ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
17.896,50
-0,14%
S&P 500
5.064,20
0,91%
Dow Jones
38.225,66
0,85%
Euro vs US Dollar
1,07333
0,03%
Bitcoin
59.516,05
0,67%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. Europa
  5. EU
  6. Crossject (ALCJ)

  7. Crossject (ALCJ) News

ALCJ

Crossject (ALCJ)

Crossject
Von:
Sortieren nach:
 Showing the most relevant articles for your search:EU:ALCJ
DatumZeitQuelleÜberschriftSymbolFirma
02/05/202417h30GlobeNewswire Inc.Crossject signs a geographic extension of ZEPIZURE® commercialization agreement in EuropeEU:ALCJCrossject
02/05/202417h30GlobeNewswire Inc.Crossject signe une extension géographique de l'accord de commercialisation de ZEPIZURE® en EuropeEU:ALCJCrossject
02/05/202417h30GlobeNewswire Inc.Crossject signs a geographic extension of ZEPIZURE® commercialization agreement in EuropeEU:ALCJCrossject
30/04/202419h05GlobeNewswire Inc.Crossject annonce le lancement d’une augmentation de capitalEU:ALCJCrossject
25/04/202407h32GlobeNewswire Inc.Crossject reports audited financial results for 2023EU:ALCJCrossject
25/04/202407h32GlobeNewswire Inc.Crossject reports audited financial results for 2023EU:ALCJCrossject
25/04/202407h32GlobeNewswire Inc.Crossject communique ses résultats financiers audités pour 2023EU:ALCJCrossject
10/04/202416h30GlobeNewswire Inc.Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital socialEU:ALCJCrossject
02/04/202418h35GlobeNewswire Inc.Crossject trading on Euronext to resume as usual on Wednesday April 3EU:ALCJCrossject
02/04/202418h35GlobeNewswire Inc.La cotation sur l’action de Crossject à Euronext reprendra comme d’habitude le mercredi 3 avrilEU:ALCJCrossject
02/04/202410h30GlobeNewswire Inc.Crossject advances in its U.S. Strategy and reports Financial Results for 2023EU:ALCJCrossject
02/04/202410h30GlobeNewswire Inc.Crossject advances in its U.S. Strategy and reports Financial Results for 2023EU:ALCJCrossject
02/04/202410h30GlobeNewswire Inc.Crossject poursuit sa stratégie de développement aux États-Unis et publie ses résultats financiers pour 2023EU:ALCJCrossject
08/03/202407h30GlobeNewswire Inc.Crossject gender equality score reaches 96/100 in 2024EU:ALCJCrossject
08/03/202407h30GlobeNewswire Inc.Le Score de l’index Egalité femmes-hommes chez Crossject atteint 96/100 en 2024EU:ALCJCrossject
08/03/202407h30GlobeNewswire Inc.Crossject gender equality score reaches 96/100 in 2024EU:ALCJCrossject
27/02/202408h30GlobeNewswire Inc.Crossject obtains a financing up to €12 million, in two tranchesEU:ALCJCrossject
27/02/202408h30GlobeNewswire Inc.Crossject obtains a financing up to €12 million, in two tranchesEU:ALCJCrossject
27/02/202408h30GlobeNewswire Inc.Crossject obtient un financement jusqu’à 12 millions d’euros en 2 tranchesEU:ALCJCrossject
06/02/202417h30GlobeNewswire Inc.Crossject publie une mise à jour stratégique de ses priorités pour 2024EU:ALCJCrossject
06/02/202417h30GlobeNewswire Inc.Crossject provides strategic update on priorities for 2024EU:ALCJCrossject
06/02/202417h30GlobeNewswire Inc.Crossject provides strategic update on priorities for 2024EU:ALCJCrossject
01/02/202418h15GlobeNewswire Inc.Crossject to host a business briefing on commercial strategy on February 6 at 17:30 CETEU:ALCJCrossject
01/02/202418h15GlobeNewswire Inc.Crossject organisera un webcast le 6 février à 17h30 pour faire le point sur sa stratégie commercialeEU:ALCJCrossject
01/02/202418h15GlobeNewswire Inc.Crossject to host a business briefing on commercial strategy on February 6 at 17:30 CETEU:ALCJCrossject
16/01/202417h15GlobeNewswire Inc.Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital socialEU:ALCJCrossject
09/01/202416h21GlobeNewswire Inc.Crossject to present at Biotech Showcase on January 9 at 16:30 PTEU:ALCJCrossject
09/01/202416h21GlobeNewswire Inc.Crossject annonce l’initiation de la couverture de son titre par ODDO BHFEU:ALCJCrossject
09/01/202416h21GlobeNewswire Inc.Crossject to present at Biotech Showcase on January 9 at 16:30 PTEU:ALCJCrossject
04/01/202418h00GlobeNewswire Inc.Crossject engage Syneos Health pour le lancement commercial du ZEPIZURE® aux États-UnisEU:ALCJCrossject
 Showing the most relevant articles for your search:EU:ALCJ

Kürzlich von Ihnen besucht

NYSE
MRK
Merck
NASDAQ
GOOGL
Alphabet
TG
CBK
Commerzbank
TG
BAYN
Bayer
CCOM
US30
US 30
TG
DTE
Deutsche Telekom
NYSE
NKE
Nike
DBI
TDXP
Tec DAX
USOTC
RHHBY
Roche (QX)
NYSE
JPM
JP Morgan Chase
AMEX
SPY
SPDR S&P 500
TG
LHA
Deutsche Lufthansa
TG
D7G
Nel ASA
NYSE
KO
Coca Cola
NYSE
XOM
Exxon Mobil
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten